NA
EGRX

Nordwand Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Nordwand Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100
Closed -$524 – 181
2024
Q1 		$524 Hold
100
– – ﹤0.01% 159
2023
Q4 		$523 Hold
100
– – ﹤0.01% 149
2023
Q3 		$1.58K Hold
100
– – ﹤0.01% 120
2023
Q2 		$1.94K Hold
100
– – ﹤0.01% 114
2023
Q1 		$2.84K Buy
+100
New +$2.97K ﹤0.01% 114

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nordwand Advisors's EGRX Position: Q2 2024 in Review

Nordwand Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 100 shares — an estimated $524 sold.

Nordwand Advisors first reported a position in EGRX in Q1 2023 and held it in 5 quarters. The position peaked at $2.84K in Q1 2023. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

  • Nordwand Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Nordwand Advisors sold 100 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $524.
  • Nordwand Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2023 and held it in 5 quarters.
  • Nordwand Advisors's Eagle Pharmaceuticals, Inc. position peaked at $2.84K in Q1 2023.
  • 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on Nordwand Advisors's 13F filing for Q2 2024, filed 5 Aug 2024.